ARKG ETF Analysis: ARK Genomic Revolution | BATS
Healthcare Equity | BATS, USA | Market Cap: 1.963m USD | 12M Return: 62.3% | US00214Q3020 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 262M
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The ARK Genomic Revolution ETF (ARKG) is an actively-managed, non-diversified ETF that invests at least 80% of its assets in domestic and foreign equity securities of companies tied to the genomics revolution theme. The fund holds positions across multiple sectors, including healthcare, information technology, materials, energy, and consumer discretionary. Listed on BATS since October 2014, ARKG falls within the Health ETF category and targets mid-cap exposure, with a market capitalization of approximately $2.2 billion USD. As a thematic fund, it focuses on companies involved in genomics-related innovation rather than tracking a broad market index, which is typical of actively-managed ETFs that concentrate holdings around a specific investment thesis.
- CRISPR gene therapy FDA approvals boost portfolio holdings
- Illumina sequencing margins pressured by new competitors
- Biotech sector rotation drives ETF inflows and volatility
As of November 11, 2026, the stock is trading at USD 46.27 with a total of 4,381,457 shares traded. Over the past week, the price has changed by -6.54%, over one month by -6.49%, over three months by +4.42% and over the past year by +62.29%.
Current recommended Stop Loss: 41.90 (which is 9.4% or 1.5 ATR below the current price).
ARK Genomic Revolution has no consensus analysts rating.